![](images/Newspaper.gif)
Seroprevalence of SARS-CoV-2 Among Children Visiting a Tertiary Hospital in Himachal Pradesh, India
SC34-SC37
Correspondence
Mohit Bajaj,
Senior Resident, Department of Paediatrics, Dr. rpgmc, Tanda at Kangra, Himachal Pradesh-176001, India.
E-mail: tandian427@gmail.com
Introduction: Research on Coronavirus Disease-2019 (COVID-19) seroprevalence in children and adolescent population across the globe is quite limited. In India, there is a dearth of data on COVID-19 seropositivity, especially in unvaccinated paediatric population, particularly in the Himalayan region.
Aim: To estimate the seroprevalence of COVID-19 in children presenting in a tertiary care health institution.
Materials and Methods: A hospital-based cross-sectional serosurvey was conducted on 500 children, from October 2021 to March 2022 in paediatric age group, attending Indira Gandhi Medical College Shimla, Himachal Pradesh, India, for various health related concerns such as fever, cough, loose stools, vomiting and fast breathing using convenience sampling. Socio-demographic profile was recorded and blood sample was drawn for COVID-19 antibody titre estimation. Chi-squared and Fisher’s-exact tests for proportions was used for testing statistical significance.
Results: A total of 500 children, age ranged from 12 hours to 17 years 7 months were enrolled with maximum children belonging to 01-05 years age group and there was slight male preponderance. Seropositivity in males (27.3%) was significantly higher than females (8.3%). Highest (42.3%) seropositivity was seen in age group of 06 months to 01 year. About 10.8% of cases were positive for Immunoglobulin (Ig)G antibody, 4.4% were positive for IgM antibody, while about 6.6% cases were positive for both antibodies.
Conclusion: The seroprevalence status of children and adolescents is quite low in this region, revealing the high susceptibility of children to SARS-CoV-2 in the study region. It further emphasises benefits of serological testing in children for SARS-CoV-2 as well as the need of safe and effective vaccination for the unimmunised, unprotected and vulnerable paediatric age group.